Trial Profile
A Phase III, Multicenter, Open-Label Long-Term Study to Assess the Safety and Tolerability of CDP870 400 mg Subcutaneously Every 4 Weeks, in Subjects With Rheumatoid Arthritis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Apr 2018
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors UCB Pharma Inc
- 18 Dec 2012 New trial record